I. Ray-Coquard

发表

Gestational choriocarcinoma

I. Vergote, S. Pignata, N. Concin, 2023, International Journal of Gynecological Cancer.

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

N. Duforet-Frebourg, J. Audoux, M. Wissler, 2023, medRxiv.

Endometrial cancer

S. Westin, A. Oaknin, V. Makker, 2021, Nature Reviews Disease Primers.

[Borderline ovarian tumours: CNGOFS Guidelines for clinical practice - Hormonal contraception and MHT/HRT after borderline ovarian tumour].

P. Pautier, C. Rousset-Jablonski, N. Chopin, 2020, Gynecologie, obstetrique, fertilite & senologie.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

C. Genestie, F. Guyon, C. Rousset-Jablonski, 2018, Bulletin du cancer.

ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019 .

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

D. Cibula, I. McNeish, D. Fischerová, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

[Treatments for rare ovarian tumors: What's new?]

F. Guyon, O. Trédan, N. Chopin, 2023, Bulletin du cancer.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

E. Kohn, A. Okamoto, D. Provencher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Gynecological carcinosarcomas: Overview and future perspectives.

C. Romeo, A. Buisson, P. Meeus, 2023, Bulletin du Cancer.

Endometrial cancer

S. Westin, A. Oaknin, V. Makker, 2021, Nature Reviews Disease Primers.

Networking for ovarian rare tumors: a significant breakthrough improving disease management

N. Chiannilkulchai, C. Genestie, F. Penault-Llorca, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.

B. Weber, I. Ray-Coquard, A. Floquet, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].

C. Genestie, F. Guyon, S. Le Guellec, 2023, Bulletin du cancer.

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

D. Stoppa-Lyonnet, C. Callens, S. Cecere, 2023, Oncogene.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

M. Mouret-Reynier, N. Colombo, A. Floquet, 2021, Gynecologic oncology.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

I. Treilleux, I. Ray-Coquard, E. Kalbacher, 2017, British Journal of Cancer.

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

M. Mirza, B. Slomovitz, A. Husain, 2023, International Journal of Gynecological Cancer.